This article is a correction to:
Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes
Thomas Morgan Hulen1*
Christina Friese1†Nikolaj Pagh Kristensen2†Joachim Stoltenborg Granhøj1Troels Holz Borch1Marlies J. W. Peeters1Marco Donia1Mads Hald Andersen1Sine Reker Hadrup2Inge Marie Svane1Özcan Met1,2*- 1National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark
- 2Department of Health Technology, Technical University of Denmark, Lyngby, Denmark
By Hulen TM, Friese C, Kristensen NP, Granhøj JS, Borch TH, Peeters MJW, Donia M, Andersen MH, Hadrup SR, Svane IM and Met Ö (2023). Front. Immunol. 14:1180997. doi: 10.3389/fimmu.2023.1180997
In the published article, there was an error in Figure 4 as published. Antigen category of “Overexpressed Antigens” was mislabeled. The corrected Figure 4 and its caption appear below.
Figure 4
Figure 4 Evaluation of tumor-specificities of yTILs produced with IL-2 alone or CPI. yTILs were stained with pooled tetramers loaded with 156 unique HLA-A2-restricted epitopes. (A) shows the number of tumor antigens yTILs from each patient had across conditions with anti-CTLA-4 group having statistically significant more specificities than alone (P value = 0.0156), while the anti-PD-1 group is not significant (P value = 0.938). (B) shows the sum of the estimated frequencies of tumor antigens across conditions. The sum est freq of the anti-CTLA-4 group is not statistically significant (P value = 0.2969). The individual specificity frequencies for each tumor antigen across 3 antigen categories are represented with a heatmap (C). “X” indicates value of 54.17%. Wilcoxon test was applied to compare paired data sets. “ns” = not significant; “*” represents the p value which is listed in the image description.
In the published article, there was also an error in Table 2 as published. Column heading of “%CD8+ of CD3+” was mislabeled and English decimal, “.” was not used. The corrected Table 2 and its caption appear below.
Table 2
Table 2 Sample overview including TILs/fragment, CD4 and CD8 frequencies, and ICS tumor stimulation for the three TME conditions.
The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: tumor-infiltrating lymphocyte (TIL), checkpoint inhibition, metastatic melanoma, cancer immunotherapy, tumor microenevironment, adoptive cell immunotherapy, DNA Barcoding
Citation: Hulen TM, Friese C, Kristensen NP, Granhøj JS, Borch TH, Peeters MJW, Donia M, Andersen MH, Hadrup SR, Svane IM and Met Ö (2024) Corrigendum: Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes. Front. Immunol. 15:1462081. doi: 10.3389/fimmu.2024.1462081
Received: 09 July 2024; Accepted: 10 July 2024;
Published: 18 July 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Hulen, Friese, Kristensen, Granhøj, Borch, Peeters, Donia, Andersen, Hadrup, Svane and Met. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Thomas Morgan Hulen, thomas.morgan.hulen@regionh.dk; Özcan Met, ozcan.met@regionh.dk
†These authors have contributed equally to this work